What Is the Ozempic Starting Dose?

The Ozempic starting dose is 0.25 mg, injected once weekly. This is not the dose that produces significant weight loss. It is a tolerance dose — its purpose is to let your body adjust to semaglutide and minimise the nausea and GI side effects that occur when doses are too high too quickly. Jumping to a higher starting dose is one of the most common reasons people experience severe nausea and abandon treatment early.

Understanding the dose escalation schedule helps set realistic expectations and reduces unnecessary side effects.

The Standard Dose Escalation Schedule

Novo Nordisk's recommended escalation for Ozempic follows a fixed timeline:

Weeks 1 to 4: 0.25 mg weekly. Starter dose. Appetite reduction is mild but present. The focus here is tolerability, not weight loss.

Weeks 5 to 8: 0.5 mg weekly. This is the first therapeutic dose. Most people notice meaningful appetite suppression. Weight loss begins to accelerate.

Week 9 onwards: 1 mg weekly. The standard maintenance dose for most patients. Produces sustained weight loss when combined with dietary changes.

Optional escalation: 2 mg weekly. Available in some markets. Prescribed when the 1 mg dose produces insufficient response. Weight loss is greater but side effects are more pronounced.

Physicians prescribing semaglutide at 2.4 mg (Wegovy) extend the escalation further, reaching the maximum dose at week 16 to 20.

Why the Slow Escalation Exists

GLP-1 receptors in the gut and brainstem need time to adapt to sustained stimulation. Moving too quickly causes the receptor system to be overwhelmed, producing intense nausea, vomiting, and in some cases, the need to stop treatment entirely.

The 4-week intervals are not arbitrary — they reflect the time needed for gastric emptying adaptation to stabilise and for the body to establish a new baseline of GLP-1 receptor sensitivity.

Patients who follow the escalation schedule as prescribed have significantly better tolerability and significantly lower dropout rates.

Common Mistakes at the Starting Phase

Eating large meals: The stomach empties more slowly on semaglutide. Large meals take longer to clear and cause nausea more readily. Smaller, more frequent meals are better tolerated.

High-fat meals: Fat slows gastric emptying independently of semaglutide. Combining the drug with high-fat meals multiplies the gastric-slowing effect and produces worse nausea.

Rushing dose escalation: Some patients feel no side effects at 0.25 mg and ask their physician to move to 1 mg immediately. This often produces severe GI effects at the higher dose, damaging adherence.

Timing: Some patients find morning injections produce more daytime nausea. Evening injections allow the peak semaglutide activity to pass during sleep. This is worth discussing with your prescribing physician.

What to Expect at Each Stage

At 0.25 mg, expect mild appetite reduction and occasional mild nausea after large meals. This is normal and expected.

At 0.5 mg, appetite suppression is more pronounced. Nausea is more common for the first two weeks after escalating. Most people adapt within ten to fourteen days.

At 1 mg, the full therapeutic effect is present. Nausea is usually minimal by this point. Energy levels often improve as blood sugar stabilises. Weight loss is consistent and measurable.

The Pakistani Patient and the Dose Question

For patients in Pakistan considering the METASLIM physician-guided GLP-1 program, the same principle applies: the 8-week protocol uses a calibrated sublingual GLP-1 dose within a structured program designed to build GLP-1 pathway support gradually. This mirrors the slow escalation logic of pharmaceutical semaglutide — starting the GLP-1 pathway gently and building consistent receptor support over time.